Amylyx Pharmaceuticals

AMLX

Market cap $1.47B

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Amylyx Pharmaceuticals, Inc. (Nasdaq: AMLX) (“Amylyx” or the “Company”) today announced that Week 24 and Week 48 results from the Phase 2 open-label HELIOS clinical trial of AMX0035, an oral, fixed-dose combination of sodium phenylbutyrate and taurursodiol, in adults living with Wolfram syndrome have been published in The Journal of Clinical Investigation, a peer-reviewed medical journal. The publication reports Week 24 and Week 48 results from the Phase 2 ope.

Amylyx Pharmaceuticals NASDAQ: AMLX is preparing for a pivotal Phase 3 readout for AVEXITIDE, its lead asset for post-bariatric hypoglycemia, or PBH, with data from the LUCIDITY trial expected in the third quarter, Co-Chief Executive Officer Joshua Cohen said at the BofA Annual Healthcare Conference.

Amylyx Pharmaceuticals, Inc. (AMLX) Presents at Bank of America Global Healthcare Conference 2026 Transcript

Amylyx Pharmaceuticals, Inc. (AMLX) Q1 2026 Earnings Call Transcript

CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $AMLX--Amylyx Pharmaceuticals Reports First Quarter 2026 Financial Results.

CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $AMLX--Amylyx Pharmaceuticals to Participate in Upcoming Investor Conferences.

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Amylyx Pharmaceuticals, Inc. (Nasdaq: AMLX) (“Amylyx” or the “Company”) today announced the launch of a U.S. Expanded Access Program (EAP) for up to 250 adults with post-bariatric hypoglycemia (PBH) to provide treatment access to avexitide, an investigational, first-in-class glucagon-like peptide-1 (GLP-1) receptor antagonist. The EAP allows U.S. physicians to request avexitide for adults with PBH following Roux-en-Y gastric bypass (RYGB) surgery who have a se.

CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $AMLX--Amylyx Pharmaceuticals to Report First Quarter 2026 Financial Results on May 7, 2026.

Shareholders are encouraged to contact the firm to discuss their rights and options at no cost or obligation. We would handle any matter on a contingent fee basis, whereby you would not be responsible for out-of-pocket payment of our legal fees or expenses.

CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $AMLX--Amylyx Pharmaceuticals to Present at the 25th Annual Needham Virtual Healthcare Conference.